Watch NWBO for the next few days, I'm uncertain if TLD will be revealed, or if they'll delay slightly longer. One thing is already established, the Phase 3 Trial for DCVax-L will be presented in a Plenary Session of the SNO Conference on November 20th. I believe the findings will be excellent for GBM, and it will become clear that all solid tumors can be used to make personalized vaccines which help fight the cancers.
Much the same is true for DCVax-Direct which will be tried in a wide variety of solid cancers when it goes into Phase 2 Trials which I believe could be registrational.
It's my hope that NWBO is partnered, not bought out, as I buy out might be in the $20 a share range, while a partnership permitting the company to grow could eventually have the price in triple digits when it's demonstrated to work in multiple solid cancers. It should be apparent from anecdotal evidence in a manner of a few years, but will take longer to obtain label modifications.
I believe if you look at it as an investment, it has the potential to be the best investment you'll ever make, but do your own DD. My advice is, act quickly or you may be paying a much higher price for the stock.
Gary |
